# Lung Cancer Medications

*generic version available

E experimental

## Chemotherapy Medications

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>Multiple</td>
<td>Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, <a href="#">click here</a>.</td>
</tr>
</tbody>
</table>

## Immunotherapy Medications

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imfinzi</td>
<td>durvalumab</td>
<td>Imfinzi is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer and inoperable non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Keytruda</td>
<td>pembrolizumab</td>
<td>Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
</tbody>
</table>
### Targeted Therapy Medications

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opdivo</strong></td>
<td>nivolumab</td>
<td>Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
<tr>
<td><strong>Tecentriq</strong></td>
<td>atezolizumab</td>
<td>Tecentriq is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small cell lung cancer and triple-negative breast cancer.</td>
</tr>
<tr>
<td><strong>Alecensa</strong></td>
<td>alectinib</td>
<td>Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).</td>
</tr>
<tr>
<td><strong>Alunbrig</strong></td>
<td>brigatinib</td>
<td>Alunbrig is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC) in people who cannot tolerate or do not respond to the older ALK inhibitor Xalkori (crizotinib).</td>
</tr>
<tr>
<td><strong>Avastin</strong></td>
<td>bevacizumab</td>
<td>Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer and ovarian, fallopian tube or primary peritoneal cancer. Mvasi is a biosimilar medication.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cyramza</td>
<td>ramucirumab</td>
<td>Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer that progresses after chemotherapy and previously treated liver cancer (hepatocellular carcinoma) in people with a high alpha fetoprotein level.</td>
</tr>
<tr>
<td>Erbitux</td>
<td>cetuximab</td>
<td>Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.</td>
</tr>
<tr>
<td>Gilotrif</td>
<td>afatinib</td>
<td>Gilotrif is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations who are being treated for the first time or who have experienced disease progression on chemotherapy.</td>
</tr>
<tr>
<td>Iressa</td>
<td>gefitinib</td>
<td>Iressa is a tyrosine kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.</td>
</tr>
<tr>
<td>Lorbrena</td>
<td>lorlatinib</td>
<td>Lorbrena is an anaplastic lymphoma kinase inhibitor approved for people with previously treated ALK-positive non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Mekinist</td>
<td>trametinib</td>
<td>Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.</td>
</tr>
<tr>
<td>Portrazza</td>
<td>necitumumab</td>
<td>Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rozlytrek</td>
<td>entrectinib</td>
<td>Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Tafinlar</td>
<td>dabrafenib</td>
<td>Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.</td>
</tr>
<tr>
<td>Tagrisso</td>
<td>osimertinib</td>
<td>Tagrisso is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time or who have experienced disease progression on a different EGFR inhibitor.</td>
</tr>
<tr>
<td>Tarceva</td>
<td>erlotinib</td>
<td>Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy.</td>
</tr>
<tr>
<td>Vitrakvi</td>
<td>larotrectinib</td>
<td>Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.</td>
</tr>
<tr>
<td>Vizimpro</td>
<td>dacomitinib</td>
<td>Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.</td>
</tr>
<tr>
<td>Xalkori</td>
<td>crizotinib</td>
<td>Xalkori is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) or ROS1 positive.</td>
</tr>
<tr>
<td>Zykadia</td>
<td>ceritinib</td>
<td>Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).</td>
</tr>
</tbody>
</table>

**Chemotherapy**

Generic Name: Multiple
**DRUG Chemotherapy**

**DRUG INDICATION**
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, [click here](#).

**DRUG Imfinzi**

**GENERIC NAME** durvalumab

**DRUG INDICATION**
Imfinzi is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer and inoperable non-small-cell lung cancer.

**DRUG Keytruda**

**GENERIC NAME** pembrolizumab

**DRUG INDICATION**
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.

**DRUG Opdivo**

**GENERIC NAME** nivolumab

**DRUG INDICATION**
Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced and intermediate or poor risk kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

**DRUG Tecentriq**

**GENERIC NAME** atezolizumab

**DRUG INDICATION**
Tecentriq is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small cell lung cancer and triple-negative breast cancer.

**DRUG Alecensa**

**GENERIC NAME** alectinib

**DRUG INDICATION**
Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).

**DRUG Alunbrig**

**GENERIC NAME** brigatinib
**DRUG** Alunbrig

**DRUG INDICATION**
Alunbrig is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC) in people who cannot tolerate or do not respond to the older ALK inhibitor Xalkori (crizotinib).

**DRUG** Avastin

**GENERIC NAME** bevacizumab

**DRUG INDICATION**
Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer and ovarian, fallopian tube or primary peritoneal cancer. Mvasi is a biosimilar medication.

**DRUG** Cyramza

**GENERIC NAME** ramucirumab

**DRUG INDICATION**
Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer that progresses after chemotherapy and previously treated liver cancer (hepatocellular carcinoma) in people with a high alpha fetoprotein level.

**DRUG** Erbitux

**GENERIC NAME** cetuximab

**DRUG INDICATION**
Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.

**DRUG** Gilotrif

**GENERIC NAME** afatinib

**DRUG INDICATION**
Gilotrif is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations who are being treated for the first time or who have experienced disease progression on chemotherapy.

**DRUG** Iressa

**GENERIC NAME** gefitinib

**DRUG INDICATION**
Iressa is a tyrosine kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

**DRUG** Lorbrena

**GENERIC NAME** lorlatinib

**DRUG INDICATION**
Lorbrena is an anaplastic lymphoma kinase inhibitor approved for people with previously treated ALK-positive non-small-cell lung cancer.
**DRUG** Mekinist  
**GENERIC NAME** trametinib  
**DRUG INDICATION**  
Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

**DRUG** Portrazza  
**GENERIC NAME** necitumumab  
**DRUG INDICATION**  
Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.

**DRUG** Rozlytrek  
**GENERIC NAME** entrectinib  
**DRUG INDICATION**  
Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

**DRUG** Tafinlar  
**GENERIC NAME** dabrafenib  
**DRUG INDICATION**  
Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

**DRUG** Tagrisso  
**GENERIC NAME** osimertinib  
**DRUG INDICATION**  
Tagrisso is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time or who have experienced disease progression on a different EGFR inhibitor.

**DRUG** Tarceva  
**GENERIC NAME** erlotinib  
**DRUG INDICATION**  
Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy.

**DRUG** Vitrakvi  
**GENERIC NAME** larotrectinib
**DRUG Vitrakvi**
**DRUG INDICATION**
Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

**DRUG Vizimpro**
**GENERIC NAME** dacomitinib
**DRUG INDICATION**
Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

**DRUG Xalkori**
**GENERIC NAME** crizotinib
**DRUG INDICATION**
Xalkori is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) or ROS1 positive.

**DRUG Zykadia**
**GENERIC NAME** ceritinib
**DRUG INDICATION**
Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).